Example A — Nurse-visit leuprolide injection
Clinical: Scheduled 22.5 mg (3-month) leuprolide depot administered by clinical staff; no physician evaluation.
Code(s): 96402 + J9217 x 3. No E/M.
Dx: C61; Z19.1 when documented.

Example B — Injection day with disease-status E/M
Clinical: Physician reviews rising PSA on ADT, orders imaging, discusses next-line options; depot injection given the same day.
Code(s): Established-patient E/M with modifier -25; 96402 + J-code units.
Dx: C61; R97.21 and Z19.2 as documented.

Example C — Degarelix start
Clinical: Loading-dose degarelix initiation for newly diagnosed metastatic disease.
Code(s): 96402 + J9155 units per documented dose.
Dx: C61; metastatic site code (e.g., C79.51) when documented.

Example D — Bone-health agent with ADT
Clinical: Denosumab administered for bone-metastasis skeletal protection alongside ADT.
Code(s): administration code per payer guidance + J0897 units [VERIFY: admin code].
Dx: C61; C79.51; Z19.2 as documented.

• Drug detail: agent, strength, dose, units administered, units wasted, lot per policy
• Order linkage: standing order or same-day order in the record
• -25 support: when an E/M is billed, its own assessment/plan documented separately from the injection

• Response data: PSA trend, testosterone, imaging reviewed and referenced
• Hormone status: sensitive vs castration-resistant stated and coded
• Drug management: risks/benefits and continuation decision for E/M leveling
• Metastatic sites: documented and coded when present

• Unit mismatches: reconcile J-code units against the documented depot strength on every claim — leuprolide math is the classic error.
• Wastage documentation: apply JW/JZ per payer policy with amounts in the record [VERIFY: policy].
• -25 scrutiny: LHRH injection days are a known modifier -25 audit target — bill the E/M only when it stands on its own.
• Status-dependent coverage: advanced agents denied when castration-resistant status or metastatic sites are not documented/coded.

• 96402 – Chemotherapy administration, subcutaneous/intramuscular, hormonal anti-neoplastic
• J9217 – Leuprolide acetate (for depot suspension), per 7.5 mg
• J9155 – Degarelix injection
• J9202 – Goserelin acetate implant — verify payability by setting [VERIFY: OPPS status]

• J0897 – Denosumab injection; administration per payer guidance [VERIFY: admin code]
• J3489 – Zoledronic acid, 1 mg — packaged (status N) in some settings [VERIFY: setting-specific status]

• 96413 – IV chemotherapy administration, first hour (e.g., docetaxel courses)
• A9607 – Lutetium Lu-177 vipivotide tetraxetan (radiopharmaceutical; nuclear medicine billing)
• Immunotherapy and targeted agents — med-onc billing with product-specific codes [VERIFY: product codes if needed]

• C61 – Malignant neoplasm of prostate (active disease under treatment)
• Z19.1 – Hormone sensitive malignancy status
• Z19.2 – Hormone resistant malignancy status (castration-resistant)
• R97.21 – Rising PSA following treatment
• C79.51 – Secondary malignant neoplasm of bone (and other metastatic-site codes as documented) [VERIFY: descriptor]

Tip: ICD-10 instructs "use additional code" with C61 for hormone sensitivity status — keep it current as the disease evolves; coverage for next-line agents depends on it.

• Drug detail: agent, strength, dose, units administered and wasted
• Response tracking: PSA/testosterone trend referenced at management visits
• Hormone status: stated and updated; castration-resistance documented when it develops
• -25 E/M: independent assessment and plan when billed with an injection
• Prescription drug management: risks/benefits and continuation decisions for oral agents

• -25 on injection-day E/M only with a separately identifiable service; a known audit target with LHRH injections. The CY2027 proposed rule would reduce the lower-valued service on -25 days by 50% [VERIFY: proposed rule — not final].
• JW / JZ wastage modifiers per payer policy [VERIFY: policy].

• Drug units, wastage, and -25 usage are recurring review targets; reconcile units at charge entry, not after denial.
• G2211-style continuity add-on reporting is changing in the CY2027 proposed rule (modifier-based, percentage of E/M RVUs) [VERIFY: proposed rule — not final].

• Facility charge capture: 96402 administration with the drug J-code and exact units; infusion services (96413-family) per the infusion center's charge structure.
• Drug status indicators: most separately payable drugs carry OPPS status K; some agents (e.g., J9202, J3489) carry restrictive or packaged status — confirm each agent in the current Addendum B [VERIFY: current SIs].
• Radiopharmaceuticals: A9607 and related agents bill under nuclear medicine with their own preparation/administration structure.

• C61 – primary on treatment claims
• Z19.1 / Z19.2 – hormone status
• C79.51 – bone metastases and other site codes as documented

Facility tip: hormone-status and metastatic-site coding must match the professional claim — drug coverage edits fire on the facility claim too.

• MAR precision: agent, dose, units administered and wasted on the medication administration record
• Order linkage: current order for each administration
• Record alignment: MAR, pharmacy log, nursing note, and charge capture must tell the same story

• Packaging rules vary: drug payability differs between office (ASP+6), HOPD, and ASC settings.
• Wastage review: JW/JZ compliance is a standing audit item on single-dose vials [VERIFY: policy].
• Site-of-care steering: commercial payers increasingly steer drug administration to lower-cost sites — watch payer site-of-care policies for infused agents.